Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): A multicentre, randomised, double-blind extension trial

The Lancet Neurology

Volumn 13, Issue 5, 2014, Pages 472-481

  Giovannoni, Gavin ^a   Gold, Ralf ^b   Selmaj, Krzysztof ^c   Havrdova, Eva ^d   Montalban, Xavier ^e   Radue, Ernst Wilhelm ^f   Stefoski, Dusan ^g   McNeill, Manjit ^h   Amaravadi, Lakshmi ^h   Sweetser, Marianne ^h   Elkins, Jacob ^h   O'Neill, Gilmore ^h  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST JOSEF HOSPITAL   (Germany)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d CHARLES UNIVERSITY   (Czech Republic)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DACLIZUMAB; DRUG ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BRONCHITIS; CONTROLLED STUDY; CZECH REPUBLIC; DISEASE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GERMANY; GLOMERULONEPHRITIS; GRAVES DISEASE; HEMATOMA; HUMAN; HUNGARY; HYPERTHYROIDISM; IMMUNOGENICITY; INDIA; INFECTIOUS COMPLICATION; INJECTION SITE ATROPHY; INJECTION SITE BLEEDING; INJECTION SITE DISCHARGE; INJECTION SITE DRYNESS; INJECTION SITE ERYTHEMA; INJECTION SITE HEMATOMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; POLAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; REMISSION; RETREATMENT; RHINOPHARYNGITIS; RUSSIAN FEDERATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UKRAINE; ULCERATIVE COLITIS; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898541046     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70039-0     Document Type: Article

References (20)

1. Martin R Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol 2012, 142:9-14.
2. bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006, 103:5941-5946.
3. bright NK cells. J Immunol 2010, 185:1311-1320.
4. bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult Scler 2011, 17:1441-1448.
5. Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 2012, 4:145ra06.
6. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013, 381:2167-2175.
7. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
8. Smith SM, De Stefano N, Jenkinson M, Matthews PM Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001, 25:466-475.
9. Smith S.M., Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002, 17:479-489.
10. Rojas MA, Carlson NG, Miller TL, Rose JW Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2009, 2:291-297.
11. Small clinical trials: issues and challenges 2001, 20-59. Design of small clinical trials, National Academy Press, Washington, DC. C.H. Evans, S.T. Ildstad (Eds.).
12. Radue E-W, Stefoski D, Gold R, McNeill M, Riester K, Elkins J Reduction in brain atrophy with extended daclizumab HYP treatment: results of SELECT and the SELECT extension study. Mult Scler 2013, 19(11 suppl):447. (abstr P977).
13. Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005, 64:236-240.
14. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009, 66:483-489.
15. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010, 9:381-390.
16. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004, 101:8705-8708.
17. de Seze J, Canva-Delcambre V, Fajardy I, et al. Autoimmune hepatitis and multiple sclerosis: a coincidental association?. Mult Scler 2005, 11:691-693.
18. von Kalckreuth V, Lohse AW, Schramm C Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis-not only beta interferon. Am J Gastroenterol 2008, 103:2147-2148.
19. Takahashi A, Kanno Y, Takahashi Y, et al. Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report. World J Gastroenterol 2008, 14:5474-5477.
20. Arruti M, Castillo-Triviño T, de la Riva P, Martí-Massó JF, López de Munain A, Olascoaga J Autoimmune hepatitis in a patient with multiple sclerosis under treatment with glatiramer acetate. Rev Neurol 2012, 55:190-192. (in Spanish).